Orphan drugs were central to FDA’s busy week of approvals, as the agency cleared two novel agents and a new use for a blockbuster biologic for rare disease indications.
FDA approved the first product from privately held Wellstat Therapeutics Corp. on Sept. 4, 2015. Xuriden (uridine triacetate), a new molecular entity pyrimidine analog, is indicated as uridine replacement for treatment of patients with the rare genetic disorder hereditary orotic aciduria (HoA)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?